IMMUNOCORE HLDGS ADS/1 (6YG) - Total Liabilities
Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) has total liabilities worth €699.62 Million EUR (≈ $817.93 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore IMMUNOCORE HLDGS ADS/1 long-term investment allocation to see how much of total assets are deployed in long-term investments.
IMMUNOCORE HLDGS ADS/1 - Total Liabilities Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of IMMUNOCORE HLDGS ADS/1.
IMMUNOCORE HLDGS ADS/1 Competitors by Total Liabilities
The table below lists competitors of IMMUNOCORE HLDGS ADS/1 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tibet Tianlu Co Ltd
SHG:600326
|
China | CN¥6.63 Billion |
|
Sinofibers Technology Co Ltd
SHE:300777
|
China | CN¥455.26 Million |
|
Svitzer Group A/S
CO:SVITZR
|
Denmark | Dkr5.62 Billion |
|
LIBERTY LAT.AMER.C DL-01
F:1LLC
|
Germany | €11.16 Billion |
|
Hong Leong Industries Bhd
KLSE:3301
|
Malaysia | RM725.26 Million |
|
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
|
China | CN¥3.02 Billion |
|
One Software Technologies Ltd
TA:ONE
|
Israel | ILA1.82 Billion |
|
HHC Changzhou Corp.
SHE:301061
|
China | CN¥1.03 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down IMMUNOCORE HLDGS ADS/1's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of IMMUNOCORE HLDGS ADS/1 to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how IMMUNOCORE HLDGS ADS/1's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual total liabilities of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €686.24 Million ≈ $802.28 Million |
+5.77% |
| 2024-12-31 | €648.79 Million ≈ $758.50 Million |
+184.36% |
| 2023-12-31 | €228.16 Million ≈ $266.74 Million |
+21.45% |
| 2022-12-31 | €187.86 Million ≈ $219.63 Million |
-- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more